205 related articles for article (PubMed ID: 33314742)
1. Downregulation of Glutamine Synthetase, not glutaminolysis, is responsible for glutamine addiction in Notch1-driven acute lymphoblastic leukemia.
Nguyen TL; Nokin MJ; Terés S; Tomé M; Bodineau C; Galmar O; Pasquet JM; Rousseau B; van Liempd S; Falcon-Perez JM; Richard E; Muzotte E; Rezvani HR; Priault M; Bouchecareilh M; Redonnet-Vernhet I; Calvo J; Uzan B; Pflumio F; Fuentes P; Toribio ML; Khatib AM; Soubeyran P; Murdoch PDS; Durán RV
Mol Oncol; 2021 May; 15(5):1412-1431. PubMed ID: 33314742
[TBL] [Abstract][Full Text] [Related]
2. Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia.
Herranz D; Ambesi-Impiombato A; Sudderth J; Sánchez-Martín M; Belver L; Tosello V; Xu L; Wendorff AA; Castillo M; Haydu JE; Márquez J; Matés JM; Kung AL; Rayport S; Cordon-Cardo C; DeBerardinis RJ; Ferrando AA
Nat Med; 2015 Oct; 21(10):1182-9. PubMed ID: 26390244
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia.
Baran N; Lodi A; Dhungana Y; Herbrich S; Collins M; Sweeney S; Pandey R; Skwarska A; Patel S; Tremblay M; Kuruvilla VM; Cavazos A; Kaplan M; Warmoes MO; Veiga DT; Furudate K; Rojas-Sutterin S; Haman A; Gareau Y; Marinier A; Ma H; Harutyunyan K; Daher M; Garcia LM; Al-Atrash G; Piya S; Ruvolo V; Yang W; Shanmugavelandy SS; Feng N; Gay J; Du D; Yang JJ; Hoff FW; Kaminski M; Tomczak K; Eric Davis R; Herranz D; Ferrando A; Jabbour EJ; Emilia Di Francesco M; Teachey DT; Horton TM; Kornblau S; Rezvani K; Sauvageau G; Gagea M; Andreeff M; Takahashi K; Marszalek JR; Lorenzi PL; Yu J; Tiziani S; Hoang T; Konopleva M
Nat Commun; 2022 May; 13(1):2801. PubMed ID: 35589701
[TBL] [Abstract][Full Text] [Related]
4. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia.
Chiang MY; Xu L; Shestova O; Histen G; L'heureux S; Romany C; Childs ME; Gimotty PA; Aster JC; Pear WS
J Clin Invest; 2008 Sep; 118(9):3181-94. PubMed ID: 18677410
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations.
Adebayo Michael AO; Ko S; Tao J; Moghe A; Yang H; Xu M; Russell JO; Pradhan-Sundd T; Liu S; Singh S; Poddar M; Monga JS; Liu P; Oertel M; Ranganathan S; Singhi A; Rebouissou S; Zucman-Rossi J; Ribback S; Calvisi D; Qvartskhava N; Görg B; Häussinger D; Chen X; Monga SP
Cell Metab; 2019 May; 29(5):1135-1150.e6. PubMed ID: 30713111
[TBL] [Abstract][Full Text] [Related]
6. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
7. Two parallel pathways connect glutamine metabolism and mTORC1 activity to regulate glutamoptosis.
Bodineau C; Tomé M; Courtois S; Costa ASH; Sciacovelli M; Rousseau B; Richard E; Vacher P; Parejo-Pérez C; Bessede E; Varon C; Soubeyran P; Frezza C; Murdoch PDS; Villar VH; Durán RV
Nat Commun; 2021 Aug; 12(1):4814. PubMed ID: 34376668
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of IDH1-R132H mutation in T cell acute lymphoblastic leukemia mouse model via the Notch1 pathway.
Liu Y; Fang B; Feng X; Jiang Y; Zeng Y; Jiang J
Tissue Cell; 2022 Feb; 74():101674. PubMed ID: 34814054
[TBL] [Abstract][Full Text] [Related]
9. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
[TBL] [Abstract][Full Text] [Related]
10. Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia.
Marchesini M; Gherli A; Montanaro A; Patrizi L; Sorrentino C; Pagliaro L; Rompietti C; Kitara S; Heit S; Olesen CE; Møller JV; Savi M; Bocchi L; Vilella R; Rizzi F; Baglione M; Rastelli G; Loiacono C; La Starza R; Mecucci C; Stegmaier K; Aversa F; Stilli D; Lund Winther AM; Sportoletti P; Bublitz M; Dalby-Brown W; Roti G
Cell Chem Biol; 2020 Jun; 27(6):678-697.e13. PubMed ID: 32386594
[TBL] [Abstract][Full Text] [Related]
11. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
[TBL] [Abstract][Full Text] [Related]
12. Convergence of the ZMIZ1 and NOTCH1 pathways at C-MYC in acute T lymphoblastic leukemias.
Rakowski LA; Garagiola DD; Li CM; Decker M; Caruso S; Jones M; Kuick R; Cierpicki T; Maillard I; Chiang MY
Cancer Res; 2013 Jan; 73(2):930-41. PubMed ID: 23161489
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
Koyama D; Kikuchi J; Hiraoka N; Wada T; Kurosawa H; Chiba S; Furukawa Y
Leukemia; 2014 Jun; 28(6):1216-26. PubMed ID: 24301524
[TBL] [Abstract][Full Text] [Related]
14. T cell acute lymphoblastic leukemia/lymphoma: a human cancer commonly associated with aberrant NOTCH1 signaling.
Pear WS; Aster JC
Curr Opin Hematol; 2004 Nov; 11(6):426-33. PubMed ID: 15548998
[TBL] [Abstract][Full Text] [Related]
15. MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia.
Pajcini KV; Xu L; Shao L; Petrovic J; Palasiewicz K; Ohtani Y; Bailis W; Lee C; Wertheim GB; Mani R; Muthusamy N; Li Y; Meijerink JPP; Blacklow SC; Faryabi RB; Cherry S; Pear WS
Sci Signal; 2017 Nov; 10(505):. PubMed ID: 29138297
[TBL] [Abstract][Full Text] [Related]
16. Glutamine synthetase limits β-catenin-mutated liver cancer growth by maintaining nitrogen homeostasis and suppressing mTORC1.
Dai W; Shen J; Yan J; Bott AJ; Maimouni S; Daguplo HQ; Wang Y; Khayati K; Guo JY; Zhang L; Wang Y; Valvezan A; Ding WX; Chen X; Su X; Gao S; Zong WX
J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36256480
[TBL] [Abstract][Full Text] [Related]
17. DDX5 is a positive regulator of oncogenic NOTCH1 signaling in T cell acute lymphoblastic leukemia.
Lin S; Tian L; Shen H; Gu Y; Li JL; Chen Z; Sun X; You MJ; Wu L
Oncogene; 2013 Oct; 32(40):4845-53. PubMed ID: 23108395
[TBL] [Abstract][Full Text] [Related]
18. PPP1CA/YAP/GS/Gln/mTORC1 pathway activates retinal Müller cells during diabetic retinopathy.
Guo Y; Cang X; Zhu L; Zhu M; Li A; Wang Z; Zhang Y; Wang X; Song E
Exp Eye Res; 2021 Sep; 210():108703. PubMed ID: 34280391
[TBL] [Abstract][Full Text] [Related]
19. The common oncogenomic program of NOTCH1 and NOTCH3 signaling in T-cell acute lymphoblastic leukemia.
Choi SH; Severson E; Pear WS; Liu XS; Aster JC; Blacklow SC
PLoS One; 2017; 12(10):e0185762. PubMed ID: 29023469
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia.
Chang YS; Gills JJ; Kawabata S; Onozawa M; Della Gatta G; Ferrando AA; Aplan PD; Dennis PA
Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37800623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
